Clinical experience with daptomycin in Europe: the first 2.5 years
| Autor: | Hans Lehmkuhl, Andres Beiras-Fernandez, Juergen Loeffler, Ricardo L. Chaves, R. Andrew Seaton, Armando Gonzalez-Ruiz |
|---|---|
| Rok vydání: | 2011 |
| Předmět: |
Adult
Male Microbiology (medical) medicine.medical_specialty Adolescent medicine.drug_class Staphylococcus Enterococcus faecium Antibiotics registry Young Adult Daptomycin cyclic lipopeptide Internal medicine medicine Humans Endocarditis Pharmacology (medical) Child Gram-Positive Bacterial Infections Original Research Aged Retrospective Studies Antibacterial agent Aged 80 and over Pharmacology biology business.industry Infant Middle Aged biology.organism_classification medicine.disease Anti-Bacterial Agents Surgery Discontinuation Europe Treatment Outcome Infectious Diseases Tolerability Child Preschool Vancomycin Female business Gram-positive infections medicine.drug |
| Zdroj: | Journal of Antimicrobial Chemotherapy |
| ISSN: | 1460-2091 0305-7453 |
| DOI: | 10.1093/jac/dkq528 |
| Popis: | Objectives: To describe the patient populations and infections being treated with daptomycin, as well as the efficacy and safety outcomes. Patients and methods: Data from the European Cubicin Outcomes Registry and Experience (EU-CORE ™ ), retrospectively collected at 118 institutions between January 2006 and August 2008, were analysed. Results: Daptomycin treatment was documented in 1127 patients with diverse infections, including complicated skin and soft tissue infections (33%), bacteraemia (22%), endocarditis (12%) and osteomyelitis (6%). It was used empirically, before microbiological results became available, in 53% of patients. Staphylococcus aureus was the most common pathogen (34%), with 52% of isolates resistant to methicillin; coagulase-negative staphylococci and enterococci were also frequent, with 22% of Enterococcus faecium isolates resistant to vancomycin. Daptomycin was used as first-line therapy in 302 (27%) patients. When used second line, the most common reasons for discontinuation of previous antibiotic were treatment failure and toxicity or intolerance. The use of concomitant antibiotics was reported in 65% of patients. Most frequent doses were 6 mg/kg (47%) and 4 mg/kg (32%). The median duration of daptomycin therapy was 10 days (range 1-246 days) in the inpatient setting and 13 days (range 2-189 days) in the outpatient setting. The overall clinical success rate was 79%, with a clinical failure rate of |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|